<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826941</url>
  </required_header>
  <id_info>
    <org_study_id>NS38062</org_study_id>
    <secondary_id>R01NS038062</secondary_id>
    <nct_id>NCT02826941</nct_id>
  </id_info>
  <brief_title>Moderate Hypothermia in Neonatal Hypoxic Ischemic Encephalopathy</brief_title>
  <official_title>Moderate Hypothermia in Neonatal Hypoxic Ischemic Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a multicenter, randomized, controlled pilot trial of moderate systemic
      hypothermia (33°C) vs normothermia (37°C) for 48 hours in infants with neonatal
      encephalopathy instituted within 6 hours of birth or hypoxic-ischemic event.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial tested the ability to initiate systemic hypothermia in outlying hospitals and
      participating tertiary care centers, and determined the incidence of adverse neurologic
      outcomes of death and developmental scores at 12 months by Bayley II or Vineland tests
      between normothermic and hypothermic groups. This trial identified potential safety outcomes,
      compared the adverse effects of hypothermia among hypoxic-ischemic encephalopathy (HIE)
      infants in the normothermic and hypothermic treatment groups, and obtained rates of adverse
      outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1999</start_date>
  <completion_date type="Actual">June 2004</completion_date>
  <primary_completion_date type="Actual">June 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or severely abnormal Psychomotor Development Index scores on Bayley II</measure>
    <time_frame>12 months</time_frame>
    <description>Death or severe outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bradycardia</measure>
    <time_frame>0-96 hours</time_frame>
    <description>number of patients with heart rate &lt; 80 bpm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>coagulopathy</measure>
    <time_frame>1-4 days of life</time_frame>
    <description>Mean Prothrombin time</description>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>by 12 months of age</time_frame>
    <description>numbers of patients who are withdrawn from support or die from multiorgan system failure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Neonatal Asphyxial Encephalopathy</condition>
  <condition>Hypoxic Ischemic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Hypothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If randomized to hypothermia, plastic bags filled with ice wrapped in a washcloth were applied to the head and body for approximately 2 hours, then the infant was placed on an adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature to 33 ± 0.5 °C for 48 hours at the participating tertiary care center. Rewarming by 0.5°C per hour was begun after 48 hours of hypothermia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normothermia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>If randomized to normothermia, rectal temperatures were maintained at 37 ± 0.5 °C per standard neonatal intensive care unit practice, using adult-size, water-circulating, cooling blanket (Cincinnati Sub-Zero Blanketrol II®, Cincinnati, OH), servo-controlled to rectal temperature of 37 ± 0.5 if baby was febrile.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hypothermia</intervention_name>
    <description>Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours</description>
    <arm_group_label>Hypothermia</arm_group_label>
    <other_name>whole body cooling</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>normothermia</intervention_name>
    <description>Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.</description>
    <arm_group_label>Normothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        One clinical indication of hypoxic-ischemic injury

          -  cord gas pH ≤ 7.0 or base deficit ≥13,

          -  initial infant gas pH &lt; 7.1,

          -  Apgar score ≤5 at 10 minutes,

          -  continued resuscitation after 5 min,

          -  fetal bradycardia with heart rate &lt; 80 beats per minute lasting ≥15 min,

          -  postnatal event O2 sat &lt;70% or arterial O2&lt;35 for 20 min with ischemia

        And two neurologic findings of neonatal encephalopathy, abnormalities of:

          -  tone,

          -  reflexes,

          -  state of consciousness,

          -  seizures,

          -  posturing,

          -  autonomic dysfunction

        Exclusion Criteria:

          -  Maternal chorioamnionitis,

          -  sepsis at birth,

          -  birth weight or head circumference &lt;10%,

          -  presumed chromosomal abnormality
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorothea D Jenkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <results_reference>
    <citation>Eicher DJ, Wagner CL, Katikaneni LP, Hulsey TC, Bass WT, Kaufman DA, Horgan MJ, Languani S, Bhatia JJ, Givelichian LM, Sankaran K, Yager JY. Moderate hypothermia in neonatal encephalopathy: efficacy outcomes. Pediatr Neurol. 2005 Jan;32(1):11-7.</citation>
    <PMID>15607598</PMID>
  </results_reference>
  <results_reference>
    <citation>Eicher DJ, Wagner CL, Katikaneni LP, Hulsey TC, Bass WT, Kaufman DA, Horgan MJ, Languani S, Bhatia JJ, Givelichian LM, Sankaran K, Yager JY. Moderate hypothermia in neonatal encephalopathy: safety outcomes. Pediatr Neurol. 2005 Jan;32(1):18-24.</citation>
    <PMID>15607599</PMID>
  </results_reference>
  <results_reference>
    <citation>Jenkins DD, Lee T, Chiuzan C, Perkel JK, Rollins LG, Wagner CL, Katikaneni LP, Bass WT, Kaufman DA, Horgan MJ, Laungani S, Givelichian LM, Sankaran K, Yager JY, Martin R. Altered circulating leukocytes and their chemokines in a clinical trial of therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy*. Pediatr Crit Care Med. 2013 Oct;14(8):786-95. doi: 10.1097/PCC.0b013e3182975cc9.</citation>
    <PMID>23897243</PMID>
  </results_reference>
  <results_reference>
    <citation>Jenkins DD, Rollins LG, Perkel JK, Wagner CL, Katikaneni LP, Bass WT, Kaufman DA, Horgan MJ, Languani S, Givelichian L, Sankaran K, Yager JY, Martin RH. Serum cytokines in a clinical trial of hypothermia for neonatal hypoxic-ischemic encephalopathy. J Cereb Blood Flow Metab. 2012 Oct;32(10):1888-96. doi: 10.1038/jcbfm.2012.83. Epub 2012 Jul 18.</citation>
    <PMID>22805873</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>July 5, 2016</last_update_submitted>
  <last_update_submitted_qc>July 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Dorothea D. Jenkins</investigator_full_name>
    <investigator_title>Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>hypothermia treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

